Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.

We are excited to present four posters with important real-world data from our differentiated pain portfolio at PainConnect 2025 and are grateful to AAPM for selecting our poster at its meeting as a ...

Clinical data supporting mechanism of action reinforce potential as a novel cancer treatmentBRISBANE, Calif., March 25, 2025 ...

A new exhibition in New York brings together a diverse collection of posters reflecting the opposing ideologies surrounding ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today ...

The poster will be presented at the European Lung ... and we hope to see this registrational trial confirm the promising safety and efficacy achieved to date.” Efti is Immutep’s proprietary ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at safety & security services stocks, ...